These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37592511)
1. Epididymal Sparing Bilateral Simple Orchiectomy: Cost-Effectiveness and Aesthetic Preservation for Men with Metastatic Prostate Cancer. Weinberg AE; Liu JJ; Sandelien M; Waite N; Reese JH Urol Pract; 2016 Mar; 3(2):112-117. PubMed ID: 37592511 [TBL] [Abstract][Full Text] [Related]
2. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image. Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982 [TBL] [Abstract][Full Text] [Related]
3. Simple and Epididymal-Sparing Orchiectomy for Surgical Castration in Stage IV Prostate Cancer. Travis H; Dubic M; Bardot J; Edwards B; Gills JR; Delacroix SE; LaCour S; Mutter M; Bell D; Westerman ME Ochsner J; 2024; 24(3):171-178. PubMed ID: 39280863 [No Abstract] [Full Text] [Related]
4. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. Chon JK; Jacobs SC; Naslund MJ J Urol; 2000 Sep; 164(3 Pt 1):735-7. PubMed ID: 10953136 [TBL] [Abstract][Full Text] [Related]
5. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. Bonzani RA; Stricker HJ; Peabody JO; Menon M J Urol; 1998 Dec; 160(6 Pt 2):2446-9. PubMed ID: 9817400 [TBL] [Abstract][Full Text] [Related]
6. Prospective randomised controlled trial comparing sub-epididymal orchiectomy versus conventional orchiectomy in metastatic carcinoma of prostate. Bapat S; Mahajan PM; Bhave AA; Kshirsagar YB; Sovani YB; Mulay A Indian J Surg; 2011 Jun; 73(3):175-7. PubMed ID: 22654325 [TBL] [Abstract][Full Text] [Related]
7. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. Mariani AJ; Glover M; Arita S J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375 [TBL] [Abstract][Full Text] [Related]
8. Significant financial differences of chemical and surgical androgen deprivation in a contemporary cohort. Paul CJ; Garje R; Kreder KJ; Mott SL; Gellhaus PT Transl Androl Urol; 2022 Sep; 11(9):1252-1261. PubMed ID: 36217391 [TBL] [Abstract][Full Text] [Related]
9. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat]. Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705 [TBL] [Abstract][Full Text] [Related]
10. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244 [TBL] [Abstract][Full Text] [Related]
11. Quality of life in low-income men after surgical castration for metastatic prostate cancer. Gaither TW; Kwan L; Villatoro J; Litwin MS Urol Oncol; 2022 Jul; 40(7):343.e7-343.e14. PubMed ID: 35581122 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. Bayoumi AM; Brown AD; Garber AM J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616 [TBL] [Abstract][Full Text] [Related]
14. Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE Duivenvoorden WCM; Naeim M; Hopmans SN; Yousef S; Werstuck GH; Dason S; Pinthus JH Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):389-397. PubMed ID: 32989260 [TBL] [Abstract][Full Text] [Related]
15. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. Raddin RS; Walko CM; Whang YE Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851 [TBL] [Abstract][Full Text] [Related]
16. Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. Tan YG; Poon RJ; Pang LJ; Villanueva A; Huang HH; Chen K; Ng TK; Tay KJ; Ho HS; Yuen JS Urol Oncol; 2020 Aug; 38(8):682.e1-682.e9. PubMed ID: 32475745 [TBL] [Abstract][Full Text] [Related]
17. Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects. Selvi I; Basar H Support Care Cancer; 2020 Sep; 28(9):4313-4326. PubMed ID: 31912363 [TBL] [Abstract][Full Text] [Related]